Would you consider chemoradiation + chemotherapy as in PORTEC-3 regimen for p53 mutated stage IA endometrial cancer, though this trial did not include those with stage IA disease?

There are not sufficient data to recommend this regimen in patients with stage IA endometrioid endometrial cancer. In subset analysis of patients with grade 3 endometrioid cancer with + LVSI, there was no difference in recurrence free or overall survival (OS) with the addition of chemotherapy. For p...

I would offer this, but likely not recommend it in the absence of other higher risk features. For example, substantial LVSI, grade 3 histology. Although patients with p53 mutated tumors seem to benefit from chemotherapy, I am reticent to recommend something with significant toxicity that we don't ha...

The use of chemotherapy for p53 mutated Stage IA endometrial cancer is investigational and is being studied under several ongoing clinical trials like the RAINBO trial.

There are prospective data pending in this space as mentioned by others.

However, we do offer to treat endometrial cancer that is G3 by histology (not mentioned in the question) and p53 null-phenotype similar to how we would treat a serous endometrial cancer.

Thus, a stage IA G3 p53 null-phenotype wo...

For a patient with endometrioid histology with p53 abnormal/mutated, I think that a discussion of chemotherapy is reasonable acknowledging that it would be extrapolating from PORTEC-3. I think that vaginal brachytherapy is likely also reasonable to add to chemotherapy in the absence of other risk fa...